Support: 888-992-3836
Copyright © 2023 InvestorsHub Inc.
Replies to post #289341 on $Rig's Platinum Penny Alerts
stervc
04/25/16 3:25 PM
#289388 RE: RIGATONI #289341
This is a real business. Here is the website of one of the new directors- http://www.immunotechlab.com/ipf/ Note the Stage 3 clinical trials in Europe. Immunology, according to the Washington Post and the Economist is "changing the way we treat cancers". https://www.washingtonpost.com/news/to-your-health/wp/2016/04/19/breakthrough-cancer-therapy-shows-growing-promise/
SAN CLEMENTE CA / ACCESSWIRE / April 25, 2016 / Reve Technologies, Inc. (BSSP) (the "Company" or "Reve") a development stage technology company is pleased to announce entered into a Purchase and Sale Agreement (the "Purchase Agreement") with Canteck Pharma, Inc., a Delaware corporation ("Canteck" or "CKPH") and certain majority shareholders of CKPH. Canteck has developed and patented technology (US 8,067,531 B2) known as Irreversible Pepsin Fraction ("IPF"). IPF is a therapeutic platform technology that can be used to facilitate a broad range of applications. It is free from neurological, gastrointestinal and hematological side effects. IPF has not shown to be subject to viral resistance and is cost effective. The Purchase Agreement sets forth the plan through which the Company acquires One Hundred Percent (100%) ownership Interest in Canteck Pharma, Inc. for its current and planned operations in Mexico through the exclusive Sub Licensing Agreement for Irreversible Pepsin Fraction specific to the Cancer indication only;
On April 19, 2016, Two Billion Two Hundred Twenty Million Eight Hundred Sixty Three Thousand Four Hundred and Four (2,220,863,404) shares of the Company’s Common Restricted Stock were agreed to be issued to Canteck Pharma, Inc., representing 54.05% of the issued and outstanding shares of Common Stock, in behalf of the Purchase Agreement with Cantech. The shares shall have non dilutable provisions.
(A) Two Billion Two Hundred Twenty Million Eight Hundred Sixty Three Thousand Four Hundred and Four (2,220,863,404) (the “Purchase Shares”) of REVE TECHNOLOGIES, INC.(“BSSP”) restricted common shares. The Purchase Shares are to carry a non-dilutable designation.
04/25/16 3:31 PM
#289390 RE: RIGATONI #289341
RIGATONI
04/26/16 9:34 AM
#289419 RE: RIGATONI #289341
04/27/16 9:32 AM
#289521 RE: RIGATONI #289341
sharky
04/27/16 10:09 AM
#289530 RE: RIGATONI #289341
04/27/16 10:26 AM
#289536 RE: RIGATONI #289341
Billybob_TX
05/13/16 9:49 AM
#290402 RE: RIGATONI #289341